TP53 and cancer: We demonstrate a novel convergence of CDK4/6 and HSP90 dual inhibition on HIF1α inhibition that is VHL-, p53-, or hypoxia-independent and which can be translated as a cancer therapy, including for tumors with Rb-deficiency.